Irinotecan in Treating Patients With Recurrent Malignant Glioma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
New Approaches to Brain Tumor Therapy Consortium
Study ID
NCT00003301
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Brain and Central Nervous System Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irinotecan in treating patients with recurrent malignant glioma.

Key Dates

Start date
Jul 31, 1998
Status verified
Sep 2005
Completion
Apr 30, 2004

Study Design

Primary purpose
TREATMENT

Locations (9)

FacilityCityStateZIPSite coordinators
University of Alabama Comprehensive Cancer CenterBirminghamAlabama35294-
H. Lee Moffitt Cancer Center and Research InstituteTampaFlorida33612-
Emory University Hospital - AtlantaAtlantaGeorgia30322-
Johns Hopkins Oncology CenterBaltimoreMaryland21231-
Massachusetts General Hospital Cancer CenterBostonMassachusetts02114-
Henry Ford HospitalDetroitMichigan48202-
Comprehensive Cancer Center of Wake Forest University Baptist Medical CenterWinston-SalemNorth Carolina27157-1082-
University of Pennsylvania Cancer CenterPhiladelphiaPennsylvania19104-
University of Texas Health Science Center at San AntonioSan AntonioTexas78284-7811-

Find similar trials in Birmingham, AL

By research site
University of Alabama Comprehensive Cancer Center· Birmingham, ALH. Lee Moffitt Cancer Center and Research Institute· Tampa, FLEmory University Hospital - Atlanta· Atlanta, GAJohns Hopkins Oncology Center· Baltimore, MDMassachusetts General Hospital Cancer Center· Boston, MAHenry Ford Hospital· Detroit, MI

Related Studies